Cargando…
A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
BACKGROUND: Molecular characteristics of cancer vary between individuals. In future, most trials will require assessment of biomarkers to allocate patients into enriched populations in which targeted therapies are more likely to be effective. The MRC FOCUS3 trial is a feasibility study to assess key...
Autores principales: | Maughan, T S, Meade, A M, Adams, R A, Richman, S D, Butler, R, Fisher, D, Wilson, R H, Jasani, B, Taylor, G R, Williams, G T, Sampson, J R, Seymour, M T, Nichols, L L, Kenny, S L, Nelson, A, Sampson, C M, Hodgkinson, E, Bridgewater, J A, Furniss, D L, Roy, R, Pope, M J, Pope, J K, Parmar, M, Quirke, P, Kaplan, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007241/ https://www.ncbi.nlm.nih.gov/pubmed/24743706 http://dx.doi.org/10.1038/bjc.2014.182 |
Ejemplares similares
-
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012) -
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009) -
MRC2020: improvements to Ximdisp and the MRC image-processing programs
por: Short, J. M., et al.
Publicado: (2023) -
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial
por: Richman, Susan D, et al.
Publicado: (2016) -
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
por: Maughan, Timothy S, et al.
Publicado: (2011)